Merck lifts full-year forecast as Keytruda sales soar
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall St mixed as Middle East tensions eclipse tech strength
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Merck (MRK) PT Raised to $120 at Cantor Fitzgerald
October 27, 2022 12:47 PM EDTCantor Fitzgerald analyst Louise Chen raised the price target on Merck (NYSE: MRK) to $120.00 (from $107.00) while maintaining an Overweight rating.
The analyst commented, ". Post a 3Q22 sales and EPS beat relative to FactSet consensus, we are reiterating our Overweight (OW) rating. We are... More
